MX2017009681A - Composiciones dispersables. - Google Patents

Composiciones dispersables.

Info

Publication number
MX2017009681A
MX2017009681A MX2017009681A MX2017009681A MX2017009681A MX 2017009681 A MX2017009681 A MX 2017009681A MX 2017009681 A MX2017009681 A MX 2017009681A MX 2017009681 A MX2017009681 A MX 2017009681A MX 2017009681 A MX2017009681 A MX 2017009681A
Authority
MX
Mexico
Prior art keywords
compositions
dispersible compositions
useful
dispersible
pediatric
Prior art date
Application number
MX2017009681A
Other languages
English (en)
Other versions
MX391192B (es
Inventor
Kumar Gupta Manish
Wasudeo MARATHE Shripad
Ramesh Tambwekar Kaustubh
Velayudhan NAIR Shreedevi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55229712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017009681(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2017009681A publication Critical patent/MX2017009681A/es
Publication of MX391192B publication Critical patent/MX391192B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a composiciones dispersables que comprenden fumarato de bedaquilina como principio activo; tales composiciones son útiles en el tratamiento de tuberculosis y sus propiedades de dispersabilidad intrínsecas se prestan por sí mismas para ser útiles en particular entre la población pediátrica o geriátrica.
MX2017009681A 2015-01-27 2016-01-26 Composiciones dispersables que comprenden fumarato de bedaquilina para uso en el tratamiento de enfermedades antibacterianas. MX391192B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN264MU2015 2015-01-27
PCT/EP2016/051545 WO2016120258A1 (en) 2015-01-27 2016-01-26 Dispersible compositions

Publications (2)

Publication Number Publication Date
MX2017009681A true MX2017009681A (es) 2017-10-18
MX391192B MX391192B (es) 2025-03-21

Family

ID=55229712

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009681A MX391192B (es) 2015-01-27 2016-01-26 Composiciones dispersables que comprenden fumarato de bedaquilina para uso en el tratamiento de enfermedades antibacterianas.

Country Status (29)

Country Link
US (2) US20180000810A1 (es)
EP (1) EP3250182B1 (es)
JP (3) JP7291458B2 (es)
KR (1) KR102631986B1 (es)
CN (2) CN107205945A (es)
AU (2) AU2016212116B2 (es)
CY (1) CY1126107T1 (es)
DK (1) DK3250182T3 (es)
EA (1) EA201791701A1 (es)
ES (1) ES2948805T3 (es)
FI (1) FI3250182T3 (es)
HK (1) HK1243644A1 (es)
HR (1) HRP20230616T1 (es)
HU (1) HUE062481T2 (es)
IL (2) IL253626B2 (es)
LT (1) LT3250182T (es)
MA (1) MA41411B1 (es)
MD (1) MD3250182T2 (es)
MX (1) MX391192B (es)
PE (1) PE20171319A1 (es)
PH (1) PH12017501331B1 (es)
PL (1) PL3250182T3 (es)
PT (1) PT3250182T (es)
RS (1) RS64308B1 (es)
SG (1) SG11201705944TA (es)
SI (1) SI3250182T1 (es)
SM (1) SMT202300188T1 (es)
UA (1) UA126891C2 (es)
WO (1) WO2016120258A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
AU2018298855B2 (en) * 2017-07-14 2024-07-18 Janssen Pharmaceutica Nv Long-acting formulations
EP3773731A1 (en) * 2018-04-05 2021-02-17 Cipla Limited Pharmaceutical formulations
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
CN122320982A (zh) * 2019-01-09 2026-07-03 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
EP4164626A4 (en) * 2020-06-15 2024-07-03 Mylan Laboratories Ltd. Combination antibacterial composition and method for antibacterial therapy
EP4164645A4 (en) * 2020-06-15 2024-07-10 The Global Alliance for TB Drug Development, Inc. COMBINED ANTIBACTERIAL COMPOSITION AND ANTIBACTERIAL THERAPY METHOD
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
TW202233168A (zh) * 2020-11-12 2022-09-01 比利時商健生藥品公司 治療非結核分枝桿菌疾病的藥物組分之組合
KR102478006B1 (ko) 2020-12-03 2022-12-15 정승찬 자동차 긴급 제동장치
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation
CN120731072A (zh) * 2022-12-17 2025-09-30 维亚治疗有限责任公司 用于治疗儿科结核病的氯法齐明迷你片剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1527050T1 (sl) 2002-07-25 2010-08-31 Janssen Pharmaceutica Nv Kinolinski derivati in njihova uporaba kot mikobakterijski inhibitorji
MXPA06013888A (es) 2004-05-28 2007-01-26 Janssen Pharmaceutica Nv Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos.
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
SG162724A1 (en) * 2005-05-25 2010-07-29 Janssen Pharmaceutica Nv Process for preparing <alpha s, beta r>-6-bromo-alpha-[2-<dimethylamino>ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
WO2009146097A1 (en) * 2008-04-02 2009-12-03 Dr. Reddy's Laboratories Ltd. Raloxifene pharmaceutical formulations
NZ591169A (en) * 2008-09-03 2012-12-21 Pfizer Combination therapy for tuberculosis
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (en) * 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
US20140075692A1 (en) * 2012-09-18 2014-03-20 Unger Marketing International, Llc. Multiuse cleaning tool handle
JP2015537013A (ja) * 2012-11-19 2015-12-24 アサンタ・アー／エス 速崩性錠剤

Also Published As

Publication number Publication date
EP3250182A1 (en) 2017-12-06
MX391192B (es) 2025-03-21
US20180000810A1 (en) 2018-01-04
IL253626B2 (en) 2024-08-01
EP3250182B1 (en) 2023-04-26
SG11201705944TA (en) 2017-08-30
AU2021204135B2 (en) 2023-10-05
MA41411B1 (fr) 2023-07-31
CA2973301A1 (en) 2016-08-04
BR112017015784A2 (pt) 2018-03-27
IL310920A (en) 2024-04-01
PL3250182T3 (pl) 2023-07-31
AU2016212116B2 (en) 2021-07-15
AU2016212116A1 (en) 2017-07-27
IL253626A0 (en) 2017-09-28
KR102631986B1 (ko) 2024-01-30
PH12017501331A1 (en) 2017-12-11
IL253626B1 (en) 2024-04-01
CN107205945A (zh) 2017-09-26
DK3250182T3 (da) 2023-06-26
US20220331307A1 (en) 2022-10-20
PH12017501331B1 (en) 2024-02-14
PE20171319A1 (es) 2017-09-07
SMT202300188T1 (it) 2023-07-20
RS64308B1 (sr) 2023-07-31
WO2016120258A1 (en) 2016-08-04
FI3250182T3 (fi) 2023-06-28
HRP20230616T1 (hr) 2023-09-29
LT3250182T (lt) 2023-07-10
JP2021098706A (ja) 2021-07-01
CN114129526A (zh) 2022-03-04
HK1243644A1 (zh) 2018-07-20
JP7291458B2 (ja) 2023-06-15
CY1126107T1 (el) 2023-11-15
KR20170106447A (ko) 2017-09-20
PT3250182T (pt) 2023-07-07
UA126891C2 (uk) 2023-02-22
SI3250182T1 (sl) 2023-08-31
JP2018502928A (ja) 2018-02-01
JP2022176982A (ja) 2022-11-30
AU2021204135A1 (en) 2021-07-15
ES2948805T3 (es) 2023-09-19
MA41411A (fr) 2017-12-05
EA201791701A1 (ru) 2017-11-30
HUE062481T2 (hu) 2023-11-28
MD3250182T2 (ro) 2023-09-30

Similar Documents

Publication Publication Date Title
MX391192B (es) Composiciones dispersables que comprenden fumarato de bedaquilina para uso en el tratamiento de enfermedades antibacterianas.
CO2022000278A2 (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
CL2018003425A1 (es) Composiciones de cannabidiol y usos de las mismas.
CL2017003404A1 (es) Compuestos antibacterianos
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
ECSP17028310A (es) Composiciones y métodos para inhibir la expresión del gen HAO1 (hidroxiácido-oxidasa 1 (glicolato-oxidasa))
MX2018011249A (es) Composiciones topicas no acuosas que comprenden una salicilanilida halogenada.
MX2018000351A (es) Composición para el cuidado de telas que comprende poliolésteres insaturados metatesizados.
MX377877B (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GT201300055A (es) Formulacion de premezcla de dexmedetomidina
PY1520796A (es) Composiciones plaguicidas y metodos relacionados
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
MX367383B (es) Metodo para fabricar una barra que comprende antitranspirante.
HK1215147A1 (zh) 眼部护理装置及方法
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
MX392574B (es) Análogos de compstatina de acción prolongada para usarse en el tratamiento de trastornos oculares
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico